Response of men with advanced prostatic carcinoma to exogenous administration of testosterone

Prout, George R.; Brewer, Walter R.

doi:10.1002/1097-0142(196711)20:11<1871::aid-cncr2820201112>3.0.co;2-d

Cited by 98 publications

(66 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are reports of so far inexplicable responses of prostatic carcinoma patients to administration of testosterone (Brendler et al, 1950;Prout & Brewer, 1967;Crowin et al, 1970). In rare cares, testosterone along led to objective improvement of the patient's condition.…”

Section: Discussionmentioning

confidence: 99%

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP

Wolf

Schulz²,

Fittler³

1991

Br J Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP

Wolf

Schulz²,

Fittler³

1991

Br J Cancer

View full text Add to dashboard Cite

“…[1][2][3] More contemporary clinical trials have shown little, if consistent evidence of a carcinogenic influence or the tendency to 'unmask' subclinical prostate cancer when TRT is prescribed to otherwise healthy hypogonadal men. [4][5][6] On the basis of lingering concerns and uncertainly, coupled with the fact that the prostate is known to be a androgensensitive organ, most evidence-based clinical guidelines recommend close surveillance of the prostate with prostate-specific antigen (PSA) and digital rectal examination among men treated with TRT.…”

Section: Introductionmentioning

confidence: 99%

Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy

et al. 2008

View full text Add to dashboard Cite

The primary objective of this study was to correlate simultaneous measures of prostate-specific antigen (PSA) and serum testosterone among large samples of eugonadal, untreated hypogonadal and hypogonadal men treated with testosterone replacement therapy (TRT). From 2001 to 2007, laboratory records were reviewed to identify men who underwent simultaneous measurement of PSA and serum testosterone levels. The data were stratified based on three groups of men: group 1 consisted of eugonadal men (T4300 ng per 100 ml) evaluated for BPH, reproductive failure or sexual dysfunction; group 2 consisted of untreated hypogonadal men (To300 ng per 100 ml); and group 3 comprised symptomatic hypogonadal men receiving TRT. Correlations were found between PSA (total and free fractions) and total serum testosterone levels among the three groups. Group 1: eugonadal men (n ¼ 385 patients), mean PSA and serum testosterone were 1.60 ng ml À1 and 484 ng 100 ml, respectively. There was no significant correlation between PSA and total serum testosterone levels (r ¼ À0.01, P ¼ 0.8). Group 2: untreated hypogonadal men (n ¼ 229 patients), mean PSA and serum testosterone were 1.49 ng ml À1 and 269 ng per 100 ml, respectively. There was no significant correlation between PSA and total serum testosterone levels (r ¼ 0.03, P ¼ 0.6). Group 3: hypogonadal men on TRT (n ¼ 229 patients and 994 individual samples analyzed) mean PSA and serum testosterone were 1.50 ng ml À1 and 555 ng per 100 ml, respectively. There was no significant correlation between PSA and serum testosterone levels (r ¼ À0.005, P ¼ 0.9). Mean total serum testosterone levels were increased significantly (Po0.001) following treatment. Mean PSA levels did not increase in a statistically or clinically significant manner following TRT (mean PSA increase from baseline 0.05 ng ml À1 , P ¼ 0.6). In conclusion, TRT does not appear to significantly influence serum PSA expression and no significant correlation was identified between PSA and serum testosterone among eugonadal, untreated hypogonadal and hypogonadal men receiving TRT.

show abstract

“…This publication and subsequent reviews and presentations led to the conventional wisdom that testosterone could cause prostate cancer, and that TRT could either induce de novo prostate cancer or unearth an occult prostate malignancy. 3,4 Indeed, an international survey published in 2007 showed that as many as 70% of healthcare providers were concerned about the association of TRT and prostate cancer. …”

Section: Wwwtrendsinmenshealthcom Trends In Urology and Men's Health mentioning

confidence: 99%

Prostate cancer and testosterone replacement therapy: what is the risk?

Carson¹,

Kirby

2017

Trends Urology & Men Health

View full text Add to dashboard Cite

T he last decade has seen a rise in testosterone replacement therapy (TRT) internationally.1 Controversy continues, however, on the impact of TRT and its effect on the prostate. While the effects of TRT on benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) are as yet unsettled, the role of TRT in prostate cancer appears to be clearer.The effects of testosterone and castration on the prostate and prostate cancer have a long history, with the sentinel publication of Charles Huggins and Clarence V. Hodges in 1941 as the first clear demonstration of the effects of withdrawing testosterone by castration or oestrogen on the progression of prostate cancer. 2 In that publication, the authors also showed that, in a single patient, withdrawal of testosterone by castration and subsequent replacement of testosterone had the deleterious effect of causing the prostate cancer to first involute then regrow. This publication and subsequent reviews and presentations led to the conventional wisdom that testosterone could cause prostate cancer, and that TRT could either induce de novo prostate cancer or unearth an occult prostate malignancy.

show abstract

Response of men with advanced prostatic carcinoma to exogenous administration of testosterone

Cited by 98 publications

References 11 publications

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP

Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy

Prostate cancer and testosterone replacement therapy: what is the risk?

Contact Info

Product

Resources

About